P012 Patients With Cancer and Preexisting Autoimmune and Inflammatory Diseases Treated by Anti-Programmed Death 1 (PD-1) Antibodies at Gustave Roussy Cancer Center

doi 10.1136/annrheumdis-2018-ewrr2019.9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Clinical Outcomes of Patients With Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated With Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

Oncologist
Cancer ResearchMedicineOncology
2019English

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

Therapeutic Advances in Medical Oncology
Oncology
2018English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Predictive Role of Computed Tomography Texture Analysis in Patients With Metastatic Urothelial Cancer Treated With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

JAMA Oncology
Cancer ResearchOncology
2018English

Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

PLoS ONE
Multidisciplinary
2019English

The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort

Oncotarget
Oncology
2017English

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

Cancer Immunotherapy With Immunomodulatory Anti-Cd137 and Anti-Pd-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Cancer Discovery
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy